COG-PSYCHO : Social Cognition and Psychotic Characteristics: Genetic and Phenomic Approach (COG-PSYCHO)

Cognition Sociale et caractéristiques Psychotiques : Approche génétique et phénomique

Bipolar disorder (BD), schizophrenia and depression can feature cognitive impairment, especially in social cognition (SC). According to previous studies, some genes from the oxytocin and dopamine pathways may be involved SC performance. Our endophenotype approach aimed to demonstrate that SC deficits are more severe in schizophrenia and BD or depression with psychotic symptoms (PBP) and are associated with certain Single Nucleotide Polymorphisms (SNPs) variants.

600 patients with schizophrenia, BD ou depression with and without psychotic symptoms will be recrited. Social Cognition was assessed using 4 paradigms: Reading the Mind in the Eyes Test (RMET), Interpersonal Reactivity Index (IRI), Empathy Quotient (QE), and a modified Delay Discounting task. After DNA extraction from blood or saliva sample, we used PCR amplification and real-time detection to genotype SNPs from Oxytocin pathways. he level of ocytocine will be also mesured.

Study Overview

• Status: Recruiting
• Conditions: Social Cognition of Schizophrenia, Bipolas or Depressed Patients
• Intervention / Treatment: Genetic: ocytocine dosage and genetic analyse

Detailed Description

Schizophrenia and mood disorders represent two severe and frequent disease with heterogeneous phenotype sharing some clinical symptoms (possible presence of psychotic symptoms in mood disorders, systematic in schizophrenia) and neurocognitive impairments including social cognition. These disorders result from an interaction of several minor effect genes with various early or late environmental factors, with psychosocial or biological origin.

The association of these pathologies with dysfunctions of major neurotransmission systems has been the subject of numerous studies, but the results have often been contradictory for methodological, clinical (phenotypic heterogeneity) and finally genetic reasons. The definition of the phenotype is an essential issue in research on the genetics of mental disorders. The risk of phenotypic misclassification of subjects during genetic studies confirms the need for a better delimitation of homogeneous patient sub-populations. The development by the National Institute of Mental Health (NIMH) of clinical research criteria is essential to bring sufficient power to modern research in genetics, but also in imaging, neuroscience or behavioral sciences of mental disorders.

The aim of our work is to study a restricted phenotype of schizophrenia and mood disorders: the assessment of social cognitions. Deficits in social cognition constitute one of the subconstructs described by the NIMH and lead to functional and clinical maladjustment hindering psychosocial rehabilitation. Indeed, oxytocin is reported to be a mediator of the regulation of social cognition (including empathy and theory of mind) and emotional behaviors (Meyer-Lindenberg, 2011).

The current project involves the analysis of several social cognition tasks that measure social perception, facial recognition of affect and empathy. The objective of this work is to highlight an association between performance on the 4 social cognition paradigms and polymorphisms of the OXT and OXTR genes and in a population of subjects suffering from schizophrenia or mood disorder with or without psychotic symptoms.

The main hypothesis of this study is that these genes have an impact on social cognition in each of the populations recruited (patients with schizophrenia or patients with a mood disorder). The secondary hypothesis is to show that this impact of the genotype is more marked in patients with psychotic symptoms (suffering from mood disorders or schizophrenia) compared to patients suffering from mood disorders without psychotic symptoms (interaction mechanism).

Main objective : To show the association between variants of the OXT and OXTR genes and the deficit in social cognition observed in patients with schizophrenia or a mood disorder with or without psychotic features.

Primary endpoint : Performance on the Reading the Mind in the Eyes Test (RMET), which measures the ability to attribute emotions to others.

Secondary Objectives :

1. To show the impact of the OXT and OXTR genes on 3 other paradigms of social cognition, and in the following subgroups: schizophrenic patients, patients with mood disorders, patients with psychotic symptoms and patients without psychotic symptoms.
2. To highlight interactions between genetic variants of the OXT and OXTR genes with the main impaired cognitive and neurological capacities in schizophrenia and mood disorders (attention, executive and memory function).
3. To search for an association between traumatic life events in childhood and delusional clinical phenotype and impaired cognition in mood disorders.
4. To demonstrate that plasma oxytocin levels are decreased in patients with psychotic symptoms compared to patients without psychotic symptoms and correlated with social cognition performance in the total sample of subjects as well as in each of these subgroups.
5. To demonstrate that OXTR gene expression is reduced in patients with psychotic symptoms (schizophrenia or mood disorder with psychotic symptoms) compared to subjects without psychotic symptoms (mood disorder without psychotic symptoms), and correlated with social cognitive performance in the total sample of subjects and in each of these subgroups.

Secondary Evaluation Criteria :

1. Performance on three other tests measuring social cognitions: Delay Discouting applied to social cognitions, Interpersonal Reactivity Index and Empathy Quotient (Berthoz et al., 2008)
2. RMET test performance
3. Potentially traumatic life events (CTQ questionnaire)
4. Plasma determination of circulating oxytocin
5. mRNA expression level of the OXTR gene measured by RT-qPCR Monocentric cross-sectional study evaluating social cognition in patients suffering from schizophrenia, mood disorder with or without psychotic symptoms in search of genetic determinants involved in social cognition performance.

Patients undergo biological sampling (genotyping of variants of the OXT and OXTR genes, quantification of circulating oxytocin and quantification of OXTR transcript expression) and undergo several evaluations (RMET, Delay Discounting, Interpersonal Reactivity Index, Empathy Quotient).

Criteria for inclusion

• Major patient under 75 years of age
• Presenting the DSM-5 criteria for schizophrenia, bipolar disorder or major depressive episode.
• Capable of giving consent or under curatorship
• Benefiting from a health insurance plan Criteria for non-inclusion Pregnancy (urine test performed prior to inclusion in the program) Procedure A single three-hour face-to-face interview will be carried out at the inclusion, in an inpatient or outpatient setting. Patients will have a 30-minute social cognition assessment by the RMET, two empathy self-questionnaires: IRI and QE, and a computerized update time stamp.

The collection of standardized psychiatric and addictological diagnoses using the DIGS is under the responsibility of Professor DUBERTRET (Hôpital Louis Mourier) in order to define the groups of subjects. There is no follow-up on a day-by-day basis; patient participation is one day.

All subjects will have a blood sample in order to perform genetic analyses including genotyping of the genes tested, quantification of OXTR mRNA expressed in peripheral venous blood (biogps) by RT-qPCR and oxytocin assay.

Number of patients 600 patients

1 (monocentric study) Duration of inclusion: 5 years Duration of participation (treatment + follow-up):1 day Total research duration 5 years

• Study Type: Interventional
• Enrollment (Anticipated): 600
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Caroline Dubertret, MD, PhD; Phone Number: 33147606409; Email: caroline.dubertret@aphp.fr

Study Locations

• France
  • Colombes, France, 92700
    • Recruiting
    • Hôpital Louis Mourier

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

"Inclusion criteria :

• - Major patient under 75 years of age
• Presenting the DSM-5 criteria for schizophrenia, bipolar disorder or major depressive episode.
• Capable of giving consent or under curatorship
• Benefiting from a health insurance plan

Exclusion criteria :

• Pregnancy (urine test performed prior to inclusion in the program)
• "

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: phenotypic data and a blood prelevment	Genetic: ocytocine dosage and genetic analyse; All patients are assessed using 4 paradigms: Reading the Mind in the Eyes Test (RMET), Interpersonal Reactivity Index (IRI), Empathy Quotient (QE), and a modified Delay Discounting task. They have a blood prelevment

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Showing an correlation between SNPs of OXT et OXTR genes and social performence observed in patients with schizophrenia and bipolar or depressed patients with or without psychotic characteristics.	performence at RMET (Reading the Mind in the Eyes Test)	5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Interpersonal Reactivity Index (IRI)	Impact of OXT, OXTR genes and social performence emesured with Interpersonal Reactivity Index (IRI) observed in patients with schizophrenia and bipolar or depressed patients with or without psychotic characteristics.	5 years
Empathy Quotient (QE)	Impact of OXT, OXTR genes and social performence emesured with Empathy Quotient (QE) observed in patients with schizophrenia and bipolar or depressed patients with or without psychotic characteristics.	5 years
modified Delay Discounting task	Impact of OXT, OXTR genes and social performence emesured with a modified Delay Discounting task observed in patients with schizophrenia and bipolar or depressed patients with or without psychotic characteristics.	5 years
Cognitive performence	correlation between SNPs of OXT et OXTR genes and general cognition scores (attention, executive and mnesisic fonction)	5 years
Potentially traumatic life events (CTQ questionnaire)	Association between traumatic events and psychotic characteristics and cognition scores	5 years
Plasma determination of circulating oxytocin	- Plasma determination of oxytocin in patients with schizophrenia and bipolar, depressed patients and those without psychotic characteristics	5 years
mRNA expression level of the OXTR gene measured by RT-qPCR	Expression of OXT et OXTR genes reduced and associated with social performence observed in patients with schizophrenia and bipolar or depressed patients with psychotic characteristics compared with those without	5 years

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris
• Investigators: Principal Investigator: Caroline Dubertret, APHP

Study record dates

Study Major Dates

• Study Start (Actual): February 4, 2019
• Primary Completion (Anticipated): February 4, 2023
• Study Completion (Anticipated): December 1, 2023

Study Registration Dates

• First Submitted: February 26, 2021
• First Submitted That Met QC Criteria: June 7, 2021
• First Posted (Actual): June 16, 2021

Study Record Updates

• Last Update Posted (Actual): October 31, 2022
• Last Update Submitted That Met QC Criteria: October 28, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Keywords: social cognition of schizophrenia, bipolas or depressed patients
• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Depression; Schizophrenia
• Other Study ID Numbers: N°IDRCB 2018-A1459-46

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No